๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Revvity, Inc. (RVTY)
NYSE: RVTY ยท Real-Time Price ยท USD
145.22
-6.37 (-4.20%)
At close: Nov 20, 2026, 4:00 PM EST
148.00
+2.78 (1.91%)
After-hours: Nov 20, 2026, 7:56 PM EST
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

The long-range plan was reiterated at 6%-8% growth, excluding potential AI upside and capital deployment. Recovery in pharma/biotech, AI-related platform demand and diagnostic cost actions are supporting growth and margin progress.

Speaker 1

I think a good place to kick it off, just a quick look back at the Analyst Day last week. Maybe just highlight a couple of the key themes, takeaways, and how we should be thinking about obviously the LRP. You reiterated, maybe just talk a little bit about some of the takeaways.

Prahlad Singh
President and CEO, Revvity

Thank you, Tycho. Good morning. It is good to be here. The Analyst Day, it was a good opportunity for us to sort of reiterate what our long-range plan is and what the puts and takes have been. Since the last time we did it was more of an introduction to what Revvity is, as we were creating it and forming it. This was a good opportunity also to do a bit of a deeper dive onto the life sciences side, and that is where we spend most of the time.

Especially as we are looking at with the advent of new technology and AI and the impact it is having on our sector, we used the opportunity to do a deeper dive onto the Signals Software business, and also the sort of infinity loop model that we all are looking at as drug candidates come out of in silico, where with the Signals Software platform, we are very well positioned to be able to help researchers design molecules. Then as it moves into the wet lab side, with our software, with our reagents, with our instruments portfolio, to be able to have an impact on how we can help researchers throughout the continuum of drug development. So, it was a really good opportunity to do that.

We also went a bit deeper onto the Signals and the research side, where Craig Monell and David Gosalvez sort of tag-teamed into how our portfolio touches customers and researchers throughout the point of drug discovery and development, and the impact our portfolio has on that. Then Max ended up concluding with our LRP. So, it was a good day. Despite certain technology and logistics issues, it ended up with a pretty good attendance.

Speaker 1

Great. We are certainly going to jump into some of the themes, AI in particular, in a minute. But maybe before we do that, just the initial 2027 framing, 6% core growth, 4% underlying market growth. Maybe just talk about the gives and takes, frankly, of both of those. What could be better for the market? What could be better for you?

Prahlad Singh
President and CEO, Revvity

Yeah. I mean, two things. One, the LRP didn't change from what we had before. So, our assumption is the market would grow around 400-600 bps , and in that, we would be 200 bps above market. So, 6%-8% was the range that we had earlier, and that's what we reiterated. There were minor puts and takes between the segments, with the software going up a bit on the life sciences side, and on the diagnostic side, immunodiagnostics coming down a smidge, and reproductive health going up a smidge. There were minor puts and takes, but overall, it was more of a reiteration of our long-range plan.

More importantly, there were two things that, as Max pointed out, one, it did not include any upside that we would see from AI, and the second aspect was it sort of did not include any capital deployment component that would impact that. So, that is sort of a gist of what we presented.

Speaker 1

Are those the biggest swing factors as you think about 2027?

Prahlad Singh
President and CEO, Revvity

I think as we look into 2027, obviously, AI is going to have an impact, and it has already started showing, as we've talked about on the platform side. But just given where that journey is, and we are starting to see that obviously for 2027, we gave some considerations on what 2027 would look like, but we've got the next, I would say, eight to 10 weeks to be able to further solidify that and come out with what it will look like, specifically at the 4Q call.

Speaker 1

One of the areas, obviously, that's improved are reagents. You're up high single digit third quarter. You're still calling for mid-single digit growth in the fourth quarter on reagents, despite some of the timing of the bulk orders. I guess, just thinking a little bit further ahead, how should we think about the durability of that into 2027 on the reagent side?

Prahlad Singh
President and CEO, Revvity

Tycho, as you look at our reagent side of the business, it has performed well, and it has been the differentiating portion of our portfolio, even during when the market downturn was ongoing. And we've started, obviously, starting to see the uplift coming out of that. From the perspective of as we are seeing the market turn around, typically as we do, the first investment goes into the CapEx side of the business, and that we've clearly started seeing with our orders outpacing revenue today. As this moves forward, we will continue to see the reagents starting to see a beneficial impact of that. Once these instruments are installed and tested and validated, that's when they go into full use. It definitely is going to have an impact on the reagent side of the business.

Speaker 1

You're kind of outgrowing the market here on the reagent side, so I want to give you an opportunity to maybe talk about some of the initiatives that you have, 24-hour delivery, customer engagement, value-based pricing. Just talk a little bit about whether there's a share gain element here as well.

Prahlad Singh
President and CEO, Revvity

I think there are two components to it. As we look at it on the reagent side, we talked through it on our Investor Day. There is the RUO antibodies, and then there is the research reagents. Both of them complement each other. On the RUO antibody side and on the research side, the focus for us is that how are we on time delivery within 24 hours, 95% of our reagents get to our customers. Quality, the amount of work that we are involved in with research and their lab bench prior to. As they start using these antibodies in the design of the epitopes that they are going to require and what is needed. It has been an historic engagement over a period of time, especially on the BioLegend side of it.

As we move onto the research reagent side of the business, those are very sticky, and they get onto programs for validation. Every program that we get on, they are a multi-year program. I think that is the benefit we are seeing, and especially with the advent of new molecules, GLP-1 is one that we have talked about. As we get into those validation protocols, the stickiness of them remain on for a long period of time. I think that is where we see some of the competitive edge and advantage with the research reagent side of the portfolio.

Speaker 1

You mentioned instruments a minute ago, mid-single digit in the third quarter, you are talking about high single digit in the fourth quarter, so an acceleration here. I guess beyond high-content screening, which we will talk about in a minute, just talk a little bit about the other platforms that are contributing.

Prahlad Singh
President and CEO, Revvity

Yeah, I think on the cellular detection side, cellular analysis side, we have already started seeing an impact of that, Tycho, and as we have talked about it, orders outpacing revenue. We have also now started seeing slowly the impact on that for the rest of the portfolio. In vivo imaging, obviously, we have got a bit of an academic slant, so that was a little lighter, but that has also started seeing generating interest. Then we have got sample prep, which was a little soft.

Speaker 1

Is there a typical lag between initial high-content screening activity and some of these downstream instruments that you talk about that are starting to benefit?

Prahlad Singh
President and CEO, Revvity

I think the cellular analysis side of the portfolio are more complex, and they are big ticket items too. As they design the spec of what a researcher and what a particular group is looking for, that requires quite a bit of discussion as we plan out that instrument. It takes more of a time from when the discussion starts to designing, to manufacturing, installation, and validation. So it is more of a, I would say, a lag time from that, but not as much on the other side of the portfolio.

Speaker 1

I guess just on the high-content side, the demand curve for boxes, no customer is the same, obviously. As we think about kind of the systems you are placing and pull through, how do you think about the next couple quarters and next year on the high-content side?

Prahlad Singh
President and CEO, Revvity

Yeah. I mean, not just high-content, but when we look at the total cellular analysis side of the portfolio, as I have said, this is one of the strongest backlog periods that we have seen for that business in my decade plus that I have been at the company. I think there are two aspects to it. One, obviously, is the fundamental recovery of the end market. Pharma biotech, I think we have clearly started seeing signs of it, and the recovery of that is well underway. But outside of that, as we look at the advent of AI, the validation component does become a bottleneck as these candidates come out of in silico design. They are looking at cellular responses, what is happening to these drug candidates, and our portfolio there is very well positioned.

I think it is just the beginning of what is happening, and if AI really does start playing a role that we think it will, I think we are just starting to see the early signs of growth to that portfolio.

Speaker 1

I guess as we think about building out the fleet of instruments more, is there any kind of framework you can put around on pull through for those boxes?

Prahlad Singh
President and CEO, Revvity

Yeah. I mean, as you know, we are open system. Our reagents, as well as other reagents, will play, whereas our reagents also play on other boxes. I would say probably what I can give you a sense of, it takes two to three quarters of a lag time before you start seeing the pull through. But as you pointed out, Tycho, we already are differentiated on the reagent side today. So I think if anything, it is going to be another accelerator, another iron in the fire as these instruments get installed.

Speaker 1

What percentage of your own reagents are going through your high-content systems?

Prahlad Singh
President and CEO, Revvity

I don't think we've really specifically quantified that. Also, it's not easy to quantify because it's tough to get a sense from a customer as to what proportion of reagents are you using which are ours versus others. We do get a lot of stickiness, given the engagement we do have, and then I think that reflects in the performance of the reagents business.

Speaker 1

I think the messaging at the Analyst Day was also just the AI opportunity is broadening out, right? Beyond high-content screening, you talked about high-throughput screening, reagents, detection, imaging, ultimately in vivo workflows. I guess, can you touch on the software side and how you think that portfolio is positioned across that theme today?

Prahlad Singh
President and CEO, Revvity

Tycho, as you pointed out, we spent a lot of time on the software side of the portfolio at the Investor Day. I think the intent really there was to go a bit more into depth because we really wanted investors to understand what that portfolio is. I mean, it has gone from primarily being focused on small molecules to large molecules. Outside of that, I mean, as we've looked at AI coming in, 2026 is historically probably the most number of NPIs that we are coming out on the software side of the business, with BioDesign, with Signals AI, with LabGistics, with Xynthetica. We've launched several NPIs, which are just at the beginning.

On the software side, as these new NPIs come in, the first version is A, as it comes out, they are beta versions that customer take, but not all the features are there. We continue to add features and modules to the software as progresses and as user group meetings happen with our customers, then they sort of provide what their need is. But really what we are seeing is that AI is turning out to be a big augmenter or an accelerator to the platform. Both on the development side, definitely, because all of our software development is AI native. What would take 18 to 36 months now gets out in a matter of months. More importantly, I think our customers are asking. We launched Signals AI, we launched the connector with Anthropic.

These are elements we are. LabGistics, that's where we spent a lot of time, David, explaining what that portfolio looks like. It really is a first fully developed AI-native workflow, which on the Signals platform allows researchers to be able to bring all the elements of their drug discovery and development on one platform. Then all of it being able to pull down LLMs, being able to pull AI agents on it, and be able to perform that work. I think, and we've just launched it with the first versions of features that would have on it. I think that's going to have a major impact on the industry, if I could say that.

Speaker 1

Just maybe one more on the broader AI ecosystem. How are you separating out AI-dedicated spend versus just broader recovery in pharma and biotech?

Prahlad Singh
President and CEO, Revvity

In terms of spend or in terms of?

Speaker 1

Well, customer spend, yeah.

Prahlad Singh
President and CEO, Revvity

Yeah. I think customer spend, if I look at on the platform side, there are three. You used to have your traditional pharma biotech customers, right? I think you are seeing that you have your traditional pharma biotech customer, and you are definitely seeing an acceleration in terms of the order pattern that is coming from them. If they were buying one high-content screening equipment as an example, they are buying multiples of them, which is a deviation from what they would do in the past. Then you have your, what I would call, non-traditional customer segment, which has sort of started evolving. Public institutions that are looking at building out datasets for public consumption, that is a new customer segment that has evolved.

Then what I would call the non-traditional, which are companies that are looking at building out LLM models that are contracting out to CROs to do the work, but they are doing the spend. So that is also, I would say, a new customer segment that has started evolving.

Speaker 1

On biopharma, you are up low double digits in the quarter, ex-Signals up high single. That was a meaningful acceleration, right? So I guess, in terms of what you are seeing, is it better budgets, better utilization, more project starts, better capital spending? Maybe just talk about the breadth of the pharma recovery.

Prahlad Singh
President and CEO, Revvity

I think, I would say it is all of the above, as you pointed out. We have started seeing definitely, it has gone from being discussion or engagement to order patterns coming in from pharma biotech. Pharma is probably earlier than large biotechs, early biotechs. We do not really play that big a role, as you know. We definitely are seeing it translating into orders now, and it is clearly a pattern starting on the CapEx side. As I said, on the reagent side, we already are doing well.

Speaker 1

Are you seeing a recovery in the early-stage biotech? I know it is smaller for you .

Prahlad Singh
President and CEO, Revvity

It is a very small segment of it, and we are starting to see some early signs of it, but it really is not material to the portfolio that we play there with.

Speaker 1

Okay. You hit on Signals, I want to go back to that. I mean, up high teens in the quarter, ARR above 20%. As this business scales, I guess, what should we be paying most attention to? Is it APV growth, ARR growth, reported organic revenue?

Prahlad Singh
President and CEO, Revvity

I think organic revenue, as we've talked about, that tends to be bumpy just given the order renewal pattern. I mean, one is you look at the SaaS side of the business, right? It's 30%-35% SaaS now. We expect that will double over the next few years to 60%, 60%, 70% SaaS. As that happens, it'll get more stabilized. But the numbers that we pay a lot of attention to tends to be around the APV and the net retention rate, and those are the elements that we are seeing continue double-digit growth. I think we expect that to stay. There'll always be some quarters up or down, but overall, as you look at annual patterns, those are the ones that we pay a lot of attention to.

Speaker 1

How do you think about your moat and the competitive landscape evolving around Signals?

Prahlad Singh
President and CEO, Revvity

I mean, Signals is the plan of record today. If you go into preclinical research and discovery, you will see most scientists, as we've said, there are more than 1 million users. 46 out of the top 50 pharma biotech customers use it today. Most clinical researchers, when they turn their laptop on, Signals pops up and it starts. Given the trajectory and the track record that we've had, I mean, I grew up in undergrad and grad lab myself using ChemDraw, and that's how my career started. I relate our Signals portfolio to a stethoscope that a medical student starts using in their medical school.

Once you use it, you are going to use your stethoscope the rest of your life. That's how the Signals platform is, and that's probably the best example I can give you as to how that really is a moat for our portfolio.

Speaker 1

What do you hear from customers on software budgets? Are they stable? Are they growing? Are they competing with dollars for AI internally within pharma? How do you think?

Prahlad Singh
President and CEO, Revvity

I think they clearly are asking for more. They are saying, as we have the user group meetings, they are saying, "We want to ensure that feature A, B, and C is what we want on the platform." I would say LabGistics has been the best example for us, is they see the As they look at their need and demand from their researchers, they see now a clear path to how AI is impacting their work and how they want the elements, whether it is around machine learning, AI, or features that they are expecting.

Xynthetica was a very good example of that, a partnership with Eli Lilly, where they wanted to be able to provide the Signals platform to hundreds of biotech companies that is in their ecosystem, is a clear example of the need that came out of the discussion from pharma biotech.

Speaker 1

I want to make sure we have spent some time on diagnostics. Immuno, ex-China grew high single digits in the third quarter, but over 20% in the U.S. Maybe just talk a little bit about the U.S. performance in particular. Is it share gains? What product segments are seeing the most upside in immuno?

Prahlad Singh
President and CEO, Revvity

Yeah, I mean, immunodiagnostics, and you know this, it is going to be now nearly a decade with the acquisition of Euroimmun, and that business has continued to do very well, especially in the U.S. We are seeing really material growth. I would say that we are still under-penetrated given the relative size of the market, so there is still a lot of traction for us in the U.S., and I think we should expect to continue to see outsized growth in the U.S. marketplace as we continue to penetrate the market to what the deserved size of the market is and what our position should be in the market. I mean, two examples that I pointed out was neuroimmunology and nephrology.

I mean, we've got proprietary tests in both those spaces. Just as we bring it into the market, introduce it, add automation to it, add the software components to it, the absorption continues to increase. Even from a clinical medicine pathway perspective, these are still under-penetrated or under-utilized tests in that market, from a physician's perspective too. As these tests get introduced, as we bring more data to our customers, to clinicians, the adoption is going to increase. You will see just more of a menu adoption, and also as we expand geographically and continue to penetrate to its relative size in the U.S., it's going to be outsized growth for us there.

Speaker 1

Is it just more data to customers? Is it more reps in the field? What does it take to continue to scale at this rate?

Prahlad Singh
President and CEO, Revvity

I think number one is being us, being able to bring it to the market through the regulatory hurdles, et cetera. The second one is just awareness. I think we see a lot of awareness at the KOL levels, whether it's at Mayo or Mount Sinai or some of the bigger institution. As that moves beyond there, the early adopters are already taking it on, but you need to see just as the mass penetration increases, that'll be the bigger driver for sustainable growth.

Speaker 1

Can you just touch on the gives and takes on margins for diagnostics? Over 30% when you exclude the China piece. I mean, that's up 600 basis points. Can you just talk a little bit about how much of that is operating changes versus mix versus other factors?

Prahlad Singh
President and CEO, Revvity

Yeah. I mean, as you know, we had put in a lot of effort, and we've talked about it throughout the year, that that's one thing we were focusing on, and especially as came around some of the cost savings that we needed to do on the diagnostic side of the business. And we've started seeing the culmination of that in terms of that taking fruition, and I think that is, I would say we are still in the middle innings of that game, and there's still work that we need to do, and we are going to continue to see the impact of that as we move into 2027.

Speaker 1

And I guess from the Investor Day, you talked about, I think 20 basis points on top of normal operating leverage. How do we think about normal operating leverage longer term for the business?

Prahlad Singh
President and CEO, Revvity

Yeah, I mean, I think from our business's perspective, we should expect our margin to be in the low to mid-30s as we move forward. We've talked about that if we grow 6%, you are going to have your 75 bps of margin improvement through 40% incremental operating leverage that profitability you're going to get. Then if you are, you're going to have 20 bps more of operating leverage that we will see. All of these measures that we have put in place, whether it's around the processes that we've put in place, the rooftop optimization that we have put in place, and then the people cost savings that we are starting to see the benefit of.

So there are a lot of irons in the fire, to use that euphemism, for us to be able to gain advantage and gain the margin improvement that we have committed to.

Speaker 1

And the mid-30s operating margin target you kind of put out there, over what timeframe is that possible in your view?

Prahlad Singh
President and CEO, Revvity

I mean, if you just do the math, we are already at 28.8%, and if you do, you see the 6%, so I would say in the next two to three, we haven't put a timeframe on that, but if you are to grow, if there's a normal market environment, that should be within our long-range plan period that we've talked about.

Speaker 1

Last one, you'll be down to two turns of leverage by the end of the year. I guess just with balance sheet improving, how are you thinking about M&A inorganic?

Prahlad Singh
President and CEO, Revvity

Yeah. I mean, I think we've been very diligent on our capital deployment, Tycho, as you saw. The last big deal we did was BioLegend, which I can't believe was already 5.5 years ago. But for us, the last two, three years gave us an opportunity to buy back nearly 12% of the company, and then I think as we look at where we are today, that was a very disciplined deployment of capital. We also had a couple of notes that we had to pay off, $600 million that we paid off in July of last year. We are going to continue to be very disciplined in our approach on capital deployment, whether it's around buyback or around acquisition. I think the strategic fit and the fiscal disciplines are two elements that we'll keep in front and center of what we do.

Speaker 1

Great. We are at time. We will leave it at that. Thanks, Prahlad.

Prahlad Singh
President and CEO, Revvity

Thank you, Tycho.